Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991550 | 0.90 | MTNR1A (0.45) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21992637 | 0.89 | PPARA (0.40) | KLK7PPARGPPARALMNATDP1 | |
| SCHEMBL21991300 | 0.89 | NPSR1 (0.39) | KLK7SMN1; SMN2MAPTPPARGPPARA | |
| SCHEMBL21992649 | 0.89 | MEN1 (0.38) | SMN1; SMN2MAPTLMNATDP1 | |
| SCHEMBL21991908 | 0.87 | MTNR1A (0.50) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21991540 | 0.86 | CYP1A1 (0.38) | MAPTPPARGPPARA | |
| SCHEMBL21991966 | 0.86 | PPARG (0.38) | PPARGPPARA | |
| SCHEMBL21992650 | 0.85 | KDM4E (0.34) | SMN1; SMN2MAPT | |
| SCHEMBL21991315 | 0.84 | HPGD (0.40) | DRD3SMN1; SMN2MAPTATMPPARG | |
| SCHEMBL21991869 | 0.83 | MTNR1A (0.48) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.